Damora Therapeutics, Inc.
DMRA
$24.16
$1.074.63%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -6,307.15% | 8.84% | -35.69% | 62.42% | -73.60% |
| Total Depreciation and Amortization | -30.00% | 11.11% | 12.50% | 114.81% | -190.00% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 105,132.57% | 0.57% | -16.75% | -90.53% | 188.37% |
| Change in Net Operating Assets | 5,062.05% | -67.35% | 926.83% | 64.55% | 41.48% |
| Cash from Operations | 121.64% | -16.94% | 8.28% | 50.59% | -35.20% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -- | -- | -- | -- | -- |
| Foreign Exchange rate Adjustments | -263.64% | -97.84% | 150.74% | 135.80% | -221.41% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 9,697.62% | -50.75% | 22.72% | 59.37% | -72.83% |